On this page
Brand-name GLP-1s like Wegovy, Zepbound, Ozempic, and Mounjaro are FDA-approved, fully reviewed for safety, and made under federal oversight. Compounded versions are mixed by pharmacies, cost far less, and are not FDA-approved. After the 2024–2025 shortages ended, routine compounding of copies largely stopped, so most people now get the brand drug unless they have a specific clinical reason for a compounded one.
For about two years, compounded semaglutide and tirzepatide were everywhere, and the reason was simple. The brand-name drugs were in short supply and cost more than a thousand dollars a month. That window has mostly closed. Knowing what separates a compounded GLP-1 from the FDA-approved version helps you read the offers you'll see online and ask a clinician the right questions.
What 'compounded' actually means
Start with the brand names, because that's the approved baseline. Semaglutide is sold as Ozempic and Wegovy by Novo Nordisk, and tirzepatide is sold as Mounjaro and Zepbound by Eli Lilly. Each one went through the full FDA approval process for safety, effectiveness, and manufacturing quality, and each is made in a tightly regulated plant with a consistent dose in every pen.
A compounded drug is different. A pharmacy mixes it to order, and it has not been through FDA review. The agency does not verify a compounded GLP-1's safety, effectiveness, or quality before it reaches you. That doesn't make it automatically unsafe, but the oversight is genuinely lighter. Two kinds of compounders sit under that single label:
- 503A pharmacies compound for one patient at a time against a specific prescription. This is the traditional model behind most telehealth GLP-1 offers.
- 503B outsourcing facilities make larger batches under stricter federal manufacturing standards, closer to what drugmakers follow, with more FDA inspection.
The FDA's compounding guidance (2024) is blunt that compounded products fill a real gap when an approved drug can't meet a patient's needs. They are not a reviewed stand-in for the approved drug.
What changed when the shortage ended
Compounded GLP-1s took off because federal law carves out an exception. When a drug sits on the FDA shortage list, compounders are allowed to make copies of it. Semaglutide and tirzepatide were both on that list from 2022 through 2024 as demand outran supply. Price did the rest. Brand list prices run north of $1,000 a month without insurance, and many plans don't cover weight loss, so a compounded version at a fraction of the cost was the only route many people could afford.
Then the shortages ended. Per the FDA's 2025 update for compounders, the agency declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, then set deadlines to wind down mass compounding once each drug was available again. For semaglutide, state-licensed (503A) pharmacies had until April 2025 and outsourcing (503B) facilities until May 2025; tirzepatide's cutoffs fell a couple of months earlier. Once a drug is off the shortage list, making copies of it is no longer permitted the way it had been.
Compounding hasn't vanished. What's left is narrower. A pharmacy can still compound a GLP-1 for a documented, patient-specific reason — say, a genuine allergy to an inactive ingredient in the approved pen, or a dose or formulation that isn't commercially made. Compounding purely to beat the brand price, with no clinical reason, is the part that's now off the table.
Cost, access, and safety
The trade-off is real, and worth being honest about. Brand-name GLP-1s are the reviewed, consistent option, with a known dose and a manufacturer standing behind them, but the sticker price is steep without coverage. Compounded versions are far cheaper and were a lifeline during the shortage. The cost of that lower price is lighter oversight and more variation in what you actually receive.
The FDA has flagged specific safety problems with compounded GLP-1s (2025), and two stand out. Dosing errors have sent people to the hospital, often because compounded products come in vials and syringes rather than pre-set pens, which leaves room to draw up the wrong amount. And some compounders have used salt forms of the drug, such as "semaglutide sodium" or "semaglutide acetate," that are not the same active ingredient as the approved medication and haven't been shown to work the same way.
A compounded GLP-1 from a licensed pharmacy under a real prescription is a reasonable option for the right person. What I steer patients away from is the gray-market version, a vial in the mail with no clinician and no idea what's actually in it.
— John Venzor, DO
So the headline risk isn't compounding done correctly by a licensed pharmacy. It's sourcing from unverified online sellers who skip the clinician entirely and ship whatever they like.
Spotting a safe source from a risky one
Whether you land on a brand-name or a compounded GLP-1, the source matters more than almost anything else. A legitimate provider runs through a licensed clinician and a licensed pharmacy, every time. Anything that skips those two steps should stop you cold. The same logic holds no matter the format, whether it's an injection or one of the newer oral GLP-1 options.
Treat these as red flags of an unsafe source, and walk away if you see them:
- No prescription or clinician involved. You add it to a cart and check out, no health review.
- No named, licensed, verifiable pharmacy standing behind the product.
- "Research use only" or "not for human consumption" labeling.
- Prices that are too good to be true.
- Powders shipped to you to mix or reconstitute yourself.
If you qualify and choose a compounded GLP-1 today, it should come with a clinical reason and a licensed pharmacy behind it, not just a lower price tag. A clinician can tell you which path fits your history, your coverage, and your budget.